SG11201810359PA - (2s)-1-[4-(3,4-dichlorophenyl)piperidin-l-yl]-3-[2-(5-methyl-l,3,4-oxadiazol-2-yl)benzo[b]furan-4-yloxy]propan-2-ol or its metabolite for treating anxiety disorders - Google Patents
(2s)-1-[4-(3,4-dichlorophenyl)piperidin-l-yl]-3-[2-(5-methyl-l,3,4-oxadiazol-2-yl)benzo[b]furan-4-yloxy]propan-2-ol or its metabolite for treating anxiety disordersInfo
- Publication number
- SG11201810359PA SG11201810359PA SG11201810359PA SG11201810359PA SG11201810359PA SG 11201810359P A SG11201810359P A SG 11201810359PA SG 11201810359P A SG11201810359P A SG 11201810359PA SG 11201810359P A SG11201810359P A SG 11201810359PA SG 11201810359P A SG11201810359P A SG 11201810359PA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- week
- compound
- pct
- oxadiazol
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property 1111111111 01110111101111111101111111 01111111110110011101110111110 MIMI Organization International Bureau (10) International Publication Number (43) International Publication Date .....0\"\"\"1 WO 2017/205399 Al 30 November 2017 (30.11.2017) WIPO I PCT (51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every A61K 31/454 (2006.01) A61P 25/22 (2006.01) kind of national protection available): AE, AG, AL, AM, (21) International Application Number: AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, PCT/US2017/034036 CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, (22) International Filing Date: HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, KP, KR, 23 May 2017 (23.05.2017) KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, (25) Filing Language: English PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, (26) Publication Language: English SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, (30) Priority Data: TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. 62/341,517 25 May 2016 (25.05.2016) US (84) Designated States (unless otherwise indicated, for every 62/373,720 11 August 2016 (11.08.2016) US kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, (71) Applicant: MINERVA NEUROSCIENCES, INC. UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, [US/US]; 1601 Trapelo Road, Suite 284, Waltham, Massa-TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, chusetts 02451 (US). EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, (72) Inventor: LUTHRINGER, Remy; 2 me de Jargonnant, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, 1207 Geneva (CH). TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). (74) Agent: ERLACHER, Heidi A. et al.; Cooley LLP, 1299 Pennsylvania Avenue, NW, Suite 700, Washington, District Declarations under Rule 4.17: of Columbia 20004 (US). — as to applicant's entitlement to apply for and be granted a = = patent (Rule 4.1700) = = Title: (2 S)-1 44-(3,4-DICHLOROPHENYL)PIPERIDIN-L-YL]-342 -(5 -METHYL-L,3,4 -OXADIAZOL-2 -YL)BENZO [ (54) B]FURAN-4-YLOXY]PROPAN-2-OL OR ITS METABOLITE FOR TREATING ANXIETY DISORDERS (57) : The present disclosure describes compositions and methods for treating at least one symptom of an anxiety disorder in a human subject. ge from Baseline (Obsered Data) by Treatment Arm The compositions and methods employ a therapeutically effective amount = — — = = Week 1 Week 2 Week 4 Week of a compound of formula I (Compound I) or formula II (Compound II, or a pharmaceutically acceptable salt, hydrate or solvate of Compound I or II. = = 6 = = _,0 = Pigure I_ = = = ( 1 ) or 11 4 V : M in -1 0 ei i i FI (ii) N ,-1 . H OH © ei C [Continued on next page] WO 2017/205399 Al MIDEDIMOMMIDIRMEM001010111101110HOHOMEMOIMIE Published: — with international search report (Art. 21(3))
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662341517P | 2016-05-25 | 2016-05-25 | |
| US201662373720P | 2016-08-11 | 2016-08-11 | |
| PCT/US2017/034036 WO2017205399A1 (en) | 2016-05-25 | 2017-05-23 | (2s)-1-[4-(3,4-dichlorophenyl)piperidin-l-yl]-3-[2-(5-methyl-l,3,4-oxadiazol-2-yl)benzo[b]furan-4-yloxy]propan-2-ol or its metabolite for treating anxiety disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201810359PA true SG11201810359PA (en) | 2018-12-28 |
Family
ID=59034882
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10202011471XA SG10202011471XA (en) | 2016-05-25 | 2017-05-23 | (2s)-1-[4-(3,4-dichlorophenyl)piperidin-l-yl]-3-[2-(5-methyl-l,3,4-oxadiazol-2-yl)benzo[b]furan-4-yloxy]propan-2-ol or its metabolite for treating anxiety disorders |
| SG11201810359PA SG11201810359PA (en) | 2016-05-25 | 2017-05-23 | (2s)-1-[4-(3,4-dichlorophenyl)piperidin-l-yl]-3-[2-(5-methyl-l,3,4-oxadiazol-2-yl)benzo[b]furan-4-yloxy]propan-2-ol or its metabolite for treating anxiety disorders |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10202011471XA SG10202011471XA (en) | 2016-05-25 | 2017-05-23 | (2s)-1-[4-(3,4-dichlorophenyl)piperidin-l-yl]-3-[2-(5-methyl-l,3,4-oxadiazol-2-yl)benzo[b]furan-4-yloxy]propan-2-ol or its metabolite for treating anxiety disorders |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US20190183874A1 (en) |
| EP (1) | EP3463357B1 (en) |
| JP (2) | JP2019516758A (en) |
| KR (2) | KR20190013847A (en) |
| CN (2) | CN109640990A (en) |
| ES (1) | ES2964790T3 (en) |
| PH (1) | PH12018502446A1 (en) |
| SG (2) | SG10202011471XA (en) |
| TW (2) | TW201808285A (en) |
| WO (1) | WO2017205399A1 (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112955145A (en) | 2018-09-04 | 2021-06-11 | 密涅瓦神经科学有限公司 | Methods of treating pain using phenoxypropylamine compounds |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100799134B1 (en) * | 1999-05-24 | 2008-01-29 | 미츠비시 웰파마 가부시키가이샤 | Phenoxypropylamine compounds |
| SA08280759B1 (en) * | 2007-01-10 | 2011-05-04 | سولفاي فارماسوتيكالز بي . في | Compounds of Cannabinoid-CB1 Antagonists and Structural Components of the Serotonin Reuptake Inhibitors Indalpine or Fluvoxamine |
| EP3925608A3 (en) * | 2013-01-24 | 2022-01-19 | Minerva Neurosciences, Inc. | Use of phenoxypropylamine compounds to treat or improve at least one disorder or parameter of sleep |
-
2017
- 2017-05-23 ES ES17729263T patent/ES2964790T3/en active Active
- 2017-05-23 WO PCT/US2017/034036 patent/WO2017205399A1/en unknown
- 2017-05-23 JP JP2018561545A patent/JP2019516758A/en active Pending
- 2017-05-23 EP EP17729263.8A patent/EP3463357B1/en active Active
- 2017-05-23 KR KR1020187036657A patent/KR20190013847A/en not_active Application Discontinuation
- 2017-05-23 TW TW106117024A patent/TW201808285A/en unknown
- 2017-05-23 KR KR1020237025156A patent/KR20230116950A/en not_active Application Discontinuation
- 2017-05-23 SG SG10202011471XA patent/SG10202011471XA/en unknown
- 2017-05-23 US US16/302,730 patent/US20190183874A1/en not_active Abandoned
- 2017-05-23 TW TW111109624A patent/TW202243675A/en unknown
- 2017-05-23 SG SG11201810359PA patent/SG11201810359PA/en unknown
- 2017-05-23 CN CN201780045454.2A patent/CN109640990A/en active Pending
- 2017-05-23 CN CN202210444218.0A patent/CN114848641A/en active Pending
-
2018
- 2018-11-20 PH PH12018502446A patent/PH12018502446A1/en unknown
-
2021
- 2021-11-29 JP JP2021192957A patent/JP7309824B2/en active Active
-
2023
- 2023-04-18 US US18/302,691 patent/US20230248714A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2017205399A1 (en) | 2017-11-30 |
| JP7309824B2 (en) | 2023-07-18 |
| TW201808285A (en) | 2018-03-16 |
| KR20230116950A (en) | 2023-08-04 |
| EP3463357A1 (en) | 2019-04-10 |
| JP2022031814A (en) | 2022-02-22 |
| US20230248714A1 (en) | 2023-08-10 |
| SG10202011471XA (en) | 2021-01-28 |
| TW202243675A (en) | 2022-11-16 |
| JP2019516758A (en) | 2019-06-20 |
| KR20190013847A (en) | 2019-02-11 |
| CN109640990A (en) | 2019-04-16 |
| CN114848641A (en) | 2022-08-05 |
| PH12018502446A1 (en) | 2019-09-09 |
| US20190183874A1 (en) | 2019-06-20 |
| ES2964790T3 (en) | 2024-04-09 |
| EP3463357B1 (en) | 2023-09-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201900135YA (en) | N-(phenylsulfonyl)benzamides and related compounds as bcl-2 inhibitors | |
| SG11201806863WA (en) | Tetracyclic pyridone compounds as antivirals | |
| SG11201809344QA (en) | Process for synthesizing 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)-pyridin-3-yl)methoxy)benzaldehyde | |
| SG11201808990QA (en) | Compositions for topical application of compounds | |
| SG11201809714TA (en) | Piperidines as menin inhibitors | |
| SG11201805300QA (en) | Heterocyclic compounds as immunomodulators | |
| SG11201804132UA (en) | Eif4-a-inhibiting compounds and methods related thereto | |
| SG11201807784SA (en) | 3-desoxy derivative and pharmaceutical compositions thereof | |
| SG11201808566WA (en) | Polymorphic form of n-{6-(2-hydroxypropan-2-yl)-2-[2-(methylsulphonyl)ethyl]-2h-indazol-5-yl}-6-(trifluoromethyl)pyridine-2-carboxamide | |
| SG11201810628XA (en) | Nasal pharmaceutical compositions with a porous excipient | |
| SG11201810280YA (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
| SG11201906436VA (en) | Novel heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same | |
| SG11201909376TA (en) | Crystalline forms of a jak inhibitor compound | |
| SG11201907356SA (en) | Piperidine-substituted mnk inhibitors and methods related thereto | |
| SG11201811686UA (en) | 18f-labeled triazole containing psma inhibitors | |
| SG11201808686VA (en) | Synthesis of indazoles | |
| SG11201907774VA (en) | Sulfoximine glycosidase inhibitors | |
| SG11201909680UA (en) | Phenyl-2-hydroxy-acetylamino-2-methyl-phenyl compounds | |
| SG11201809531SA (en) | BINDING MOLECULES SPECIFIC FOR FCγGAMMA RIIA AND USES THEREOF | |
| SG11201901850XA (en) | Dopamine-b-hydroxylase inhibitors | |
| SG11201809882XA (en) | Pharmaceutical combinations for treating cancer | |
| SG11201809162XA (en) | 6-aminopyridin-3-yl thiazoles as modulators of ror?t | |
| SG11201811804QA (en) | Oxadiazolopyridine derivates for use as ghrelin o-acyl transferase (goat) inhibitors | |
| SG11201803816RA (en) | Targeting of the formyl-peptide receptor 2/lipoxin a4 receptor (fpr2/alx) for treatment of heart disease | |
| SG11201900214UA (en) | Iso-citrate dehydrogenase (idh) inhibitor |